$Bio-Path Holdings (BPTH.US)$Reuters· 1 min ago Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-a as Treatment for Obesity in Type 2 Diabetes Patients
$Bio-Path Holdings (BPTH.US)$Bio-Path Holdings Receives Patent No. 17/339,366 Titled, "P-ethoxy Nucleic Acids for STAT3 Inhibition." From United States Patent And Trademark Office
2
Report
SmellyStipes
:
how do you get these news alerts so quick? how do you know which ones to jump on?
Trytosaveabit
OPSmellyStipes
:
Theres different breaking news sites! as far as jumping in. Practice and knowing how to read the chart / volume! Also theres never a guarantee when you get in! But risk management and knowing that a loss is possible but limit it if you’re wrong
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Bio-Path Holdings Stock Forum
Bio-Path Slashes Annual Losses While Breakthrough Obesity Treatment Shows Promise
Breakthrough: Bio-Path's Novel Drug Could Transform Diabetes and Obesity Treatment
Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-a as Treatment for Obesity in Type 2 Diabetes Patients
#pleaseDontScareMe
No comment yet